Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Steen Marten					2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE]							Relationship of eck all applications X	able)	g Perso	10% Ow	ner	
(Last)	C/O ULTRAGENYX PHARMACEUTICAL INC.						3. Date of Earliest Transaction (Month/Day/Year) 01/30/2014								Other (sp below)	pecify	
60 LEVERONI COURT					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) NOVATO CA		A	94949									X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(St	ate)	(Zip)														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/Date)					Execution Da			Code (Inst	n Disposed	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)		Beneficia	es Form ally (D) of following (I) (II		Direct Condinect Extr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		"	nstr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr 8)				6. Date Exercisable ar Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$21	01/30/2014		A		17,500		(1)	01/29/2024	Common Stock	17,500	\$0.00	17,500		D		

Explanation of Responses:

1. The option shall vest with respect to 1/36th of the shares monthly such that the options shall be fully vested on the third anniversary of the grant date.

Remarks:

/s/ Shalini Sharp, by power of attorney for Marten Steen

02/03/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.